Unithroid Shortage: What Providers and Prescribers Need to Know in 2026

Levothyroxine is among the most commonly prescribed medications in primary care and endocrinology, with over 120 million prescriptions dispensed annually in the United States. When supply issues arise — even at the pharmacy level rather than the manufacturing level — the clinical and administrative burden falls directly on prescribers. This briefing provides an up-to-date overview of Unithroid and levothyroxine supply in 2026, with practical clinical protocols for managing your thyroid patients through periods of constrained availability.

Current Availability Status (2026)

As of 2026, oral levothyroxine tablets — including Unithroid — are not listed on the FDA's official drug shortage database. However, real-world availability is uneven:

Common strengths (25-125 mcg): Broadly available at most pharmacies.

Higher strengths (137, 175, 200, 300 mcg): Intermittently unavailable at chain pharmacies; independent pharmacies are more reliable.

Levothyroxine injection (IV): Active ASHP shortage for Sagent 500 mcg vial; does not affect oral tablet supply.

Overall oral availability: Approximately 92% based on real-world pharmacy check data (medfinder, May 2026).

Key Events Affecting 2026 Supply

Two 2025 events continue to shape the 2026 supply picture:

March 2025 — Kaiser Permanente supply reduction: Kaiser notified members of a critical reduction in generic levothyroxine supply from their preferred manufacturer. Patients were restricted to 30-day supplies. This created demand pressure on other levothyroxine brands including Unithroid.

August 2025 — FDA enforcement on desiccated thyroid products: The FDA took enforcement action against unapproved animal-derived thyroid products. Patients previously on those preparations (e.g., certain NP Thyroid, Nature-Throid formulations) needed to transition back to levothyroxine — increasing demand on the conventional levothyroxine supply chain.

Why Levothyroxine Is Uniquely Vulnerable to Supply Disruption

Understanding the structural factors helps clinicians counsel patients and plan proactively:

Narrow therapeutic index (NTI): FDA bioequivalence standards allow 80-125% potency variation. Even AB-rated generics can cause clinically meaningful TSH shifts in sensitive patients. NTI status requires strict manufacturing quality control, slowing production and increasing batch failure risk.

Multiple SKUs: 12 separate tablet strengths require 12 production runs. Less-common strengths are produced less frequently, creating periodic gaps.

Brand-switching restrictions: Most states require prescriber authorization to switch between brand-name levothyroxine products — creating an administrative bottleneck during shortages.

Clinical Protocols: Switching from Unithroid to an Alternative

When a patient cannot obtain Unithroid, the following switching protocol applies:

Unithroid → Generic levothyroxine: 1:1 microgram conversion. Recheck TSH 6-8 weeks post-switch. Recommend staying with the same generic manufacturer across refills.

Unithroid → Synthroid: 1:1 conversion. Recheck TSH 6-8 weeks. Both contain lactose and comparable inactive ingredients.

Unithroid → Tirosint: 1:1 conversion, but Tirosint's superior absorption (gel capsule, no fillers) may produce a lower TSH than expected. Recheck at 6 weeks; consider dose reduction if TSH drops below target.

Unithroid → Euthyrox: 1:1 conversion. Recheck TSH 6-8 weeks.

Priority Patient Groups: Who Cannot Safely Miss Doses

If supply is constrained, prioritize continuity for these patient groups:

Post-thyroidectomy patients: No endogenous T4 production whatsoever; completely dependent on exogenous levothyroxine.

Thyroid cancer patients on TSH suppression: Inadequate dosing may allow tumor regrowth; TSH suppression is part of the treatment protocol.

Pregnant patients: Levothyroxine requirements increase by 20-30% during pregnancy; inadequate dosing is associated with impaired fetal neurodevelopment and preterm birth. Monitor TSH every 4 weeks in first half of pregnancy.

Neonates with congenital hypothyroidism: Critical for normal cognitive and physical development; missed doses must not occur.

Drug Interactions Relevant to Availability Management

When counseling patients on Unithroid (or any levothyroxine formulation), reinforce these key interaction points, especially during any brand transition:

Proton pump inhibitors (PPIs) — reduce absorption; implicated in ~70% of levothyroxine drug interaction cases. Patients on PPIs may benefit from Tirosint's superior absorption profile.

Warfarin — levothyroxine potentiates anticoagulant effect; INR monitoring essential during any dosage adjustment or brand switch.

Calcium and iron supplements — must be separated by 4 hours; failure to counsel on this is a common cause of under-treatment.

Antiepileptics (carbamazepine, phenytoin) and rifampin — increase hepatic metabolism of levothyroxine; may require dose increase.

Resources and Tools for Your Practice

medfinder for Providers — calls pharmacies on behalf of patients to find Unithroid in stock; reduces staff call burden.

FDA Drug Shortage Database (accessdata.fda.gov) — monitor for changes in official status.

ASHP Drug Shortage Resource Center (ashp.org/drug-shortages) — often flags issues before the FDA list; includes injectable levothyroxine shortage data.

American Thyroid Association guidelines (thyroid.org) — evidence-based guidance on levothyroxine prescribing, monitoring, and switching.

For a step-by-step protocol on helping patients locate Unithroid, see our provider's guide to helping patients find Unithroid.